{"id":63261,"date":"2026-04-15T22:44:23","date_gmt":"2026-04-15T14:44:23","guid":{"rendered":"https:\/\/flcube.com\/?p=63261"},"modified":"2026-04-15T22:44:24","modified_gmt":"2026-04-15T14:44:24","slug":"fosun-pharma-advances-dual-target-car-t-therapy-fkc289-into-clinical-trials-for-rare-kidney-and-blood-disorders","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63261","title":{"rendered":"Fosun Pharma Advances Dual-Target CAR-T Therapy FKC289 into Clinical Trials for Rare Kidney and Blood Disorders"},"content":{"rendered":"\n<p><strong>Shanghai Fosun Pharmaceutical Group Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600196:SHA\">SHA: 600196<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/2196:HKG\">HKG: 2196<\/a>) announced it has received regulatory approval from the <strong>National Medical Products Administration (NMPA)<\/strong> to initiate <strong>two Phase I\/II clinical studies<\/strong> for <strong>FKC289<\/strong>, its innovative <strong>dual-target chimeric antigen receptor (CAR)-T cell therapy<\/strong> targeting both <strong>BCMA and CD19<\/strong>, in two rare disease indications: <strong>relapsed\/refractory primary light chain amyloidosis<\/strong> and <strong>relapsed\/refractory membranous nephropathy<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Shanghai Fosun Pharmaceutical Group Co., Ltd. (SHA: 600196, HKG: 2196)<\/td><\/tr><tr><td><strong>Regulatory Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial authorization<\/td><\/tr><tr><td><strong>Study Phases<\/strong><\/td><td>Phase I\/II (combined)<\/td><\/tr><tr><td><strong>Number of Studies<\/strong><\/td><td>Two separate clinical trials<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>FKC289 \u2013 dual-target CAR-T cell therapy<\/td><\/tr><tr><td><strong>Targets<\/strong><\/td><td>BCMA and CD19 (simultaneous targeting)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-indication-profiles\">Indication Profiles<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-primary-light-chain-amyloidosis-al-amyloidosis\">Primary Light Chain Amyloidosis (AL Amyloidosis)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Disease Type<\/strong>: Rare plasma cell disorder characterized by abnormal light chain protein deposition in organs<\/li>\n\n\n\n<li><strong>Pathology<\/strong>: Misfolded immunoglobulin light chains accumulate in tissues, particularly heart and kidneys<\/li>\n\n\n\n<li><strong>Current Treatment<\/strong>: Limited options for relapsed\/refractory cases; poor prognosis with median survival of 6-12 months<\/li>\n\n\n\n<li><strong>Therapeutic Rationale<\/strong>: BCMA targeting addresses plasma cell origin; CD19 targeting may eliminate precursor B-cells<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-membranous-nephropathy-mn\">Membranous Nephropathy (MN)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Disease Type<\/strong>: Autoimmune kidney disorder causing nephrotic syndrome<\/li>\n\n\n\n<li><strong>Pathology<\/strong>: Autoantibodies against podocyte antigens lead to glomerular basement membrane damage<\/li>\n\n\n\n<li><strong>Current Treatment<\/strong>: Immunosuppressive therapies with significant toxicity and variable efficacy<\/li>\n\n\n\n<li><strong>Therapeutic Rationale<\/strong>: CD19 targeting eliminates autoreactive B-cells; BCMA targeting may address plasma cell contribution<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-innovation\">Technology Innovation<\/h2>\n\n\n\n<p><strong>FKC289<\/strong> represents a <strong>next-generation CAR-T approach<\/strong> with several distinguishing features:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual-Target Design<\/strong>: Simultaneous targeting of BCMA (B-cell maturation antigen) and CD19 addresses multiple cell populations involved in disease pathogenesis<\/li>\n\n\n\n<li><strong>Novel Indications<\/strong>: First CAR-T therapy being evaluated in these specific rare disease settings<\/li>\n\n\n\n<li><strong>Platform Expansion<\/strong>: Demonstrates Fosun&#8217;s capability to adapt CAR-T technology beyond traditional oncology applications<\/li>\n\n\n\n<li><strong>Mechanism Rationale<\/strong>: Dual targeting may prevent antigen escape and provide more comprehensive disease control<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-fosun-pharma\">For Fosun Pharma<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Diversification<\/strong>: Expands CAR-T portfolio beyond hematologic malignancies into autoimmune and rare diseases<\/li>\n\n\n\n<li><strong>Innovation Leadership<\/strong>: Positions Fosun at forefront of next-generation CAR-T development in China<\/li>\n\n\n\n<li><strong>Commercial Opportunity<\/strong>: Addresses significant unmet needs in rare diseases with limited treatment options<\/li>\n\n\n\n<li><strong>Global Potential<\/strong>: Success in rare diseases could support international regulatory submissions<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-rare-disease-treatment-landscape\">For Rare Disease Treatment Landscape<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Paradigm Shift<\/strong>: CAR-T therapy represents potential disease-modifying approach versus current symptomatic treatments<\/li>\n\n\n\n<li><strong>Patient Impact<\/strong>: Could transform prognosis for patients with currently poor survival outcomes<\/li>\n\n\n\n<li><strong>Scientific Validation<\/strong>: Tests hypothesis that B-cell\/plasma cell targeting is effective in non-oncologic indications<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-context\">Competitive Context<\/h2>\n\n\n\n<p>The <strong>dual-target CAR-T approach<\/strong> differentiates FKC289 from single-target CAR-T therapies currently in development or approved for various indications. Key competitive advantages include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Reduced Escape Risk<\/strong>: Dual targeting minimizes likelihood of antigen-negative disease recurrence<\/li>\n\n\n\n<li><strong>Broader Cell Elimination<\/strong>: Targets both mature plasma cells (BCMA+) and precursor B-cells (CD19+)<\/li>\n\n\n\n<li><strong>Novel Application<\/strong>: First-mover advantage in these specific rare disease indications<\/li>\n\n\n\n<li><strong>Chinese Innovation<\/strong>: Demonstrates domestic capability in advanced cell therapy development<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-industry-outlook\">Industry Outlook<\/h2>\n\n\n\n<p>Fosun&#8217;s advancement of FKC289 reflects the <strong>expanding application of CAR-T technology<\/strong> beyond traditional oncology into autoimmune and rare diseases. The dual-target approach represents an evolution in CAR-T design aimed at addressing the complex cellular ecosystems involved in these conditions.<\/p>\n\n\n\n<p>If successful, FKC289 could establish new treatment paradigms for diseases with limited therapeutic options, while also validating the broader applicability of CAR-T technology in non-malignant conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/600196_20260415_I6YU.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600196_20260415_I6YU.\"><\/object><a id=\"wp-block-file--media-673936e1-3711-4040-838c-1d12ebf98e3f\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/600196_20260415_I6YU.pdf\">600196_20260415_I6YU<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/600196_20260415_I6YU.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-673936e1-3711-4040-838c-1d12ebf98e3f\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Fosun Pharmaceutical Group Co., Ltd. (SHA: 600196, HKG: 2196) announced it has received regulatory&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[21,62,159,893,892],"class_list":["post-63261","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-car-t","tag-clinical-trial-approval-initiation","tag-fosun-pharmaceutical","tag-hkg-2196","tag-sha-600196"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Fosun Pharma Advances Dual-Target CAR-T Therapy FKC289 into Clinical Trials for Rare Kidney and Blood Disorders - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Fosun Pharmaceutical Group Co., Ltd. (SHA: 600196, HKG: 2196) announced it has received regulatory approval from the National Medical Products Administration (NMPA) to initiate two Phase I\/II clinical studies for FKC289, its innovative dual-target chimeric antigen receptor (CAR)-T cell therapy targeting both BCMA and CD19, in two rare disease indications: relapsed\/refractory primary light chain amyloidosis and relapsed\/refractory membranous nephropathy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63261\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fosun Pharma Advances Dual-Target CAR-T Therapy FKC289 into Clinical Trials for Rare Kidney and Blood Disorders\" \/>\n<meta property=\"og:description\" content=\"Shanghai Fosun Pharmaceutical Group Co., Ltd. (SHA: 600196, HKG: 2196) announced it has received regulatory approval from the National Medical Products Administration (NMPA) to initiate two Phase I\/II clinical studies for FKC289, its innovative dual-target chimeric antigen receptor (CAR)-T cell therapy targeting both BCMA and CD19, in two rare disease indications: relapsed\/refractory primary light chain amyloidosis and relapsed\/refractory membranous nephropathy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63261\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-15T14:44:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-15T14:44:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63261#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63261\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Fosun Pharma Advances Dual-Target CAR-T Therapy FKC289 into Clinical Trials for Rare Kidney and Blood Disorders\",\"datePublished\":\"2026-04-15T14:44:23+00:00\",\"dateModified\":\"2026-04-15T14:44:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63261\"},\"wordCount\":548,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CAR-T\",\"Clinical trial approval \\\/ initiation\",\"Fosun Pharmaceutical\",\"HKG: 2196\",\"SHA: 600196\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63261#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63261\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63261\",\"name\":\"Fosun Pharma Advances Dual-Target CAR-T Therapy FKC289 into Clinical Trials for Rare Kidney and Blood Disorders - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-15T14:44:23+00:00\",\"dateModified\":\"2026-04-15T14:44:24+00:00\",\"description\":\"Shanghai Fosun Pharmaceutical Group Co., Ltd. (SHA: 600196, HKG: 2196) announced it has received regulatory approval from the National Medical Products Administration (NMPA) to initiate two Phase I\\\/II clinical studies for FKC289, its innovative dual-target chimeric antigen receptor (CAR)-T cell therapy targeting both BCMA and CD19, in two rare disease indications: relapsed\\\/refractory primary light chain amyloidosis and relapsed\\\/refractory membranous nephropathy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63261#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63261\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63261#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fosun Pharma Advances Dual-Target CAR-T Therapy FKC289 into Clinical Trials for Rare Kidney and Blood Disorders\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Fosun Pharma Advances Dual-Target CAR-T Therapy FKC289 into Clinical Trials for Rare Kidney and Blood Disorders - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Fosun Pharmaceutical Group Co., Ltd. (SHA: 600196, HKG: 2196) announced it has received regulatory approval from the National Medical Products Administration (NMPA) to initiate two Phase I\/II clinical studies for FKC289, its innovative dual-target chimeric antigen receptor (CAR)-T cell therapy targeting both BCMA and CD19, in two rare disease indications: relapsed\/refractory primary light chain amyloidosis and relapsed\/refractory membranous nephropathy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63261","og_locale":"en_US","og_type":"article","og_title":"Fosun Pharma Advances Dual-Target CAR-T Therapy FKC289 into Clinical Trials for Rare Kidney and Blood Disorders","og_description":"Shanghai Fosun Pharmaceutical Group Co., Ltd. (SHA: 600196, HKG: 2196) announced it has received regulatory approval from the National Medical Products Administration (NMPA) to initiate two Phase I\/II clinical studies for FKC289, its innovative dual-target chimeric antigen receptor (CAR)-T cell therapy targeting both BCMA and CD19, in two rare disease indications: relapsed\/refractory primary light chain amyloidosis and relapsed\/refractory membranous nephropathy.","og_url":"https:\/\/flcube.com\/?p=63261","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-15T14:44:23+00:00","article_modified_time":"2026-04-15T14:44:24+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63261#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63261"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Fosun Pharma Advances Dual-Target CAR-T Therapy FKC289 into Clinical Trials for Rare Kidney and Blood Disorders","datePublished":"2026-04-15T14:44:23+00:00","dateModified":"2026-04-15T14:44:24+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63261"},"wordCount":548,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CAR-T","Clinical trial approval \/ initiation","Fosun Pharmaceutical","HKG: 2196","SHA: 600196"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63261#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63261","url":"https:\/\/flcube.com\/?p=63261","name":"Fosun Pharma Advances Dual-Target CAR-T Therapy FKC289 into Clinical Trials for Rare Kidney and Blood Disorders - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-15T14:44:23+00:00","dateModified":"2026-04-15T14:44:24+00:00","description":"Shanghai Fosun Pharmaceutical Group Co., Ltd. (SHA: 600196, HKG: 2196) announced it has received regulatory approval from the National Medical Products Administration (NMPA) to initiate two Phase I\/II clinical studies for FKC289, its innovative dual-target chimeric antigen receptor (CAR)-T cell therapy targeting both BCMA and CD19, in two rare disease indications: relapsed\/refractory primary light chain amyloidosis and relapsed\/refractory membranous nephropathy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63261#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63261"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63261#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Fosun Pharma Advances Dual-Target CAR-T Therapy FKC289 into Clinical Trials for Rare Kidney and Blood Disorders"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63261","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63261"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63261\/revisions"}],"predecessor-version":[{"id":63264,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63261\/revisions\/63264"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63261"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63261"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63261"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}